SoftwareONE Posts 22.5% Revenue Surge in 2025 on Crayon Acquisition 
Private Credit Under Pressure: Is a Slow-Motion Crisis Unfolding? 
OpenAI Executive Shake-Up Ahead of Anticipated 2026 IPO 
UAE's Largest Natural Gas Facility Suspended After Attack-Triggered Fire 
Jefferies Upgrades Sodexo to Buy With €55 Target After Historic CEO Appointment 
Luxury Car Sales in the Middle East Take a Hit Amid Iran War 
Russell 1000 Companies Hit $2.2T Cash Record While Aggressively Reinvesting in Growth 
Tesla Q1 2026 Deliveries Miss Estimates as AI Strategy Takes Center Stage 
Apple Turns 50: From Garage Startup to AI Crossroads 
CTOC Adds 3,000 Doctors, 500 Hospitals Ahead of Liquidity Push 
RBC Capital: European Medtech Firms Show Minimal Middle East and Energy Risk Exposure 
TSMC Japan's Second Fab to Produce 3nm Chips by 2028 
Ukrainian Drones and the #MadeByHousewives Movement: Kyiv Fires Back at Rheinmetall CEO 
Star Entertainment Secures $390M Refinancing Deal to Stabilize Operations 
McDonald's and Restaurant Brands International Face Headwinds Amid Iran Conflict and Rising Costs 
Europe's Aviation Sector on Track to Meet 2025 Green Fuel Mandate 
Trump Administration Plans 100% Tariffs on Pharmaceutical Imports 
BRISBANE, Calif., Dec. 13, 2016 -- KaloBios Pharmaceuticals, Inc. (OTC:KBIO), a biopharmaceutical company focused on advancing medicines for patients with neglected and rare diseases, announced that Cameron Durrant, MD, chairman and CEO, will discuss how Priority Review Vouchers (PRVs) can continue to be effective incentives to help underserved patients during a panel at the U.S. Food and Drug Administration (FDA) / Centers for Medicare and Medicaid Services (CMS) Summit in Washington, D.C., December 14-15, 2016.
Dr. Durrant will also participate in a separate discussion on the significant needs in pediatric drug development.
“Important incentives, such as the PRV system, can support new approaches to bring treatments to many categories of underserved patients, including children,” said Dr. Durrant. “I look forward to engaging regulatory, policy and other stakeholders on how we could further collaborate and share ideas to help overlooked populations.”
Details of the panels follow:
Title: Priority Review Voucher Proliferation: Bane of FDA, Boon for Industry?
Date: Wednesday, December 14, 2016
Time: 3:30 – 4:00 p.m. EST
Participants: Krista Carver, Covington & Burling LLP; Dr. Gayatri Rao, Office of Orphan Products Development, FDA; Dr. Cameron Durrant, KaloBios Pharmaceuticals
Title: Pediatric Drug Development
Date: Thursday, December 15, 2016
Time: 11:15 a.m. – 12:00 p.m. EST
Participants: Dr. Mary Dianne Murphy, Office of Pediatric Therapeutics, FDA (retired); Dr. Stephen Yoo, REGENXBIO; Dr. Cameron Durrant, KaloBios Pharmaceuticals
For more information on the conference, please visit https://lifesciences.knect365.com/fda-cms/.
About KaloBios Pharmaceuticals, Inc.
KaloBios Pharmaceuticals, Inc. (OTC:KBIO) is an emerging biopharmaceutical company focused on advancing medicines for patients with neglected and rare diseases through innovative and responsible business models. Lead compounds in the KaloBios portfolio are benznidazole for the potential treatment of Chagas disease in the U.S., and the proprietary monoclonal antibodies, lenzilumab and ifabotuzumab (formerly KB004), for the potential treatment of various solid and hematologic cancers such as CMML and potentially JMML. For more information, visit www.kalobios.com.
Investors: Mike Cole O: 949-259-4988 C: 949-444-1341 [email protected] Media: Lisa Guiterman O: 301-217-9353 C: 202-330-3431 [email protected]
